1620582-23-1
Chemical Structure
LEI-106
- CAS No.: 1620582-23-1
- Formula:C26H27NO6S
- Molecular Weight:481.56
IUPAC Name: N-((2,2-dimethylchroman-6-yl)sulfonyl)-N-(4-phenoxybenzyl)glycine
InChIKey: FOEGBOXMDBPYEV-UHFFFAOYSA-N
SMILES: OC(CN(CC1=CC=C(OC2=CC=CC=C2)C=C1)S(C3=CC=C4OC(C)(CCC4=C3)C)(=O)=O)=O
Biological Activity: LEI-106 is a dual ABHD6 and DAGL-α inhibitor, with a Ki of 0.8 μM for ABHD6, and an IC50 of 18 nM and a Ki of 0.7 μM for DAGL-α. LEI-106 blocks the synthesis of 2-arachidonoylglycerol, reduces the level of endothelial cell-derived 2-arachidonoylglycerol, without altering the levels of cannabinoids and diacylglycerol. LEI-106 is applicable to research related to diet-induced obesity and metabolic syndrome[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LEI-106 | 98.86% | LEI-106 is a dual ABHD6 and DAGL-α inhibitor, with a Ki of 0.8 μM for ABHD6, and an IC50 of 18 nM and a Ki of 0.7 μM for DAGL-α. LEI-106 blocks the synthesis of 2-arachidonoylglycerol, reduces the level of endothelial cell-derived 2-arachidonoylglycerol, without altering the levels of cannabinoids and diacylglycerol. LEI-106 is applicable to research related to diet-induced obesity and metabolic syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Janssen FJ, et al. Discovery of glycine sulfonamides as dual inhibitors of sn-1-diacylglycerol lipase α and α/β-hydrolase domain 6. J Med Chem. 2014;57(15):6610-6622. [Content Brief]
- [2]. Levine AA, et al. Depletion of Endothelial-Derived 2-AG Reduces Blood-Endothelial Barrier Integrity via Alteration of VE-Cadherin and the Phospho-Proteome. Int J Mol Sci. 2023;25(1):531. Published 2023 Dec 30. [Content Brief]
Keywords
